Compass Pathways announces second quarter 2024 financial results and business highlights Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in...
Compass Pathways appoints Lori Englebert as Chief Commercial Officer New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent...
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005...
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder Study met primary safety...
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360...
Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved...
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors David Norton Assumes Role of Interim Board Chair while the...
Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Highlights: COMP360 phase 3 pivotal program ongoing;...
Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved...
Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement Three-year research collaboration will investigate the development of scalable, commercial delivery...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.